Paul Horstmeier - Jun 7, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Jun 7, 2021
Transactions value $: -$382,195
Form type: 4
Date filed: 6/9/2021, 09:17 PM
Previous filing: Jun 3, 2021
Next filing: Jul 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$96K	+6.06K	+5.24%	$15.84	122K	Jun 7, 2021	Direct
transaction	HCAT	Common Stock	Sale	-$64.6K	-1.2K	-0.99%	$53.77	121K	Jun 7, 2021	Direct	F1, F2
transaction	HCAT	Common Stock	Sale	-$16.4K	-300	-0.25%	$54.65	120K	Jun 7, 2021	Direct	F1, F3
transaction	HCAT	Common Stock	Sale	-$252K	-4.52K	-3.76%	$55.87	116K	Jun 7, 2021	Direct	F1, F4
transaction	HCAT	Common Stock	Sale	-$2.54K	-45	-0.04%	$56.37	116K	Jun 7, 2021	Direct	F1, F5
transaction	HCAT	Common Stock	Sale	-$29.3K	-545	-0.47%	$53.73	115K	Jun 7, 2021	Direct	F1, F6
transaction	HCAT	Common Stock	Sale	-$11K	-200	-0.17%	$54.76	115K	Jun 7, 2021	Direct	F1, F7
transaction	HCAT	Common Stock	Sale	-$102K	-1.83K	-1.59%	$55.90	113K	Jun 7, 2021	Direct	F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-6.06K	-5.92%	$0.00	96.4K	Jun 7, 2021	Common Stock	6.06K	$15.84	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F2	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $53.23 to $54.10, inclusive.
F3	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.23 to $54.95, inclusive.
F4	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.30 to $56.27, inclusive.
F5	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $56.36 to $56.40, inclusive.
F6	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $53.25 to $54.03, inclusive.
F7	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.27 to $55.24, inclusive.
F8	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.43 to $56.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) through (8).
F9	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.